ReviewIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2025
Diagnosis of infected pancreatic necrosis: A review of the role of blood biomarkers.
Review in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infected pancreatic necrosis (IPN) is a serious and critical complication of acute pancreatitis (AP), often arising in the later stages of the disease. Early detection of high-risk individuals with IPN is essential because it may enable clinicians to implement more efficient management strategies. This review explores the key biomarkers currently used to predict and diagnose IPN. Established markers such as procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) play a vital role in detecting infection and inflammation. Non-invasive markers, including corticosteroid-binding globulin (CBG), neutrophil CD64 index (nCD64), soluble PD-L1 (sPD-L1) and human leukocytes antigen-DR (HLA-DR), further contribute to identifying immune suppression and infection risks. While these tools show promise, no single biomarker has proven to be sufficiently accurate. A combination of clinical assessment, imaging and multiple biomarkers is essential for a comprehensive diagnosis. This review emphasizes the need for further research to refine and validate these markers, making them more accessible and reliable for routine clinical use. By advancing our ability to identify IPN early, we can improve patient outcomes and reduce the severe impacts of this complication in individuals suffering from AP.
Indexed as
Identifiers
40601134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.